132 related articles for article (PubMed ID: 37126006)
1. Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma.
Draghi A; Presti M; Jensen AWP; Chamberlain CA; Albieri B; Rasmussen AK; Andersen MH; Crowther MD; Svane IM; Donia M
Clin Cancer Res; 2023 Oct; 29(19):3937-3947. PubMed ID: 37126006
[TBL] [Abstract][Full Text] [Related]
2. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
3. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA
J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
Friedman KM; Prieto PA; Devillier LE; Gross CA; Yang JC; Wunderlich JR; Rosenberg SA; Dudley ME
J Immunother; 2012 Jun; 35(5):400-8. PubMed ID: 22576345
[TBL] [Abstract][Full Text] [Related]
5. Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.
Donia M; Andersen R; Kjeldsen JW; Fagone P; Munir S; Nicoletti F; Andersen MH; Thor Straten P; Svane IM
Cancer Res; 2015 Sep; 75(18):3747-59. PubMed ID: 26183926
[TBL] [Abstract][Full Text] [Related]
6. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
7. Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.
Hishii M; Kurnick JT; Ramirez-Montagut T; Pandolfi F
Clin Exp Immunol; 1999 Jun; 116(3):388-94. PubMed ID: 10361224
[TBL] [Abstract][Full Text] [Related]
8. Antigen-Presenting Intratumoral B Cells Affect CD4
Bruno TC; Ebner PJ; Moore BL; Squalls OG; Waugh KA; Eruslanov EB; Singhal S; Mitchell JD; Franklin WA; Merrick DT; McCarter MD; Palmer BE; Kern JA; Slansky JE
Cancer Immunol Res; 2017 Oct; 5(10):898-907. PubMed ID: 28848053
[TBL] [Abstract][Full Text] [Related]
9. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
Nishimura MI; Avichezer D; Custer MC; Lee CS; Chen C; Parkhurst MR; Diamond RA; Robbins PF; Schwartzentruber DJ; Rosenberg SA
Cancer Res; 1999 Dec; 59(24):6230-8. PubMed ID: 10626817
[TBL] [Abstract][Full Text] [Related]
10. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
11. Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes.
Ksander BR; Geer DC; Chen PW; Salgaller ML; Rubsamen P; Murray TG
Curr Eye Res; 1998 Feb; 17(2):165-73. PubMed ID: 9523095
[TBL] [Abstract][Full Text] [Related]
12. HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance.
Stupia S; Heeke C; Brüggemann A; Zaremba A; Thier B; Kretz J; Sucker A; Philip M; Zelinskyy G; Ferrone S; Roesch A; Horn S; Hadaschik E; Schadendorf D; Trilling M; Dittmer U; Griewank K; Zhao F; Paschen A
Clin Cancer Res; 2023 Aug; 29(15):2894-2907. PubMed ID: 37199727
[TBL] [Abstract][Full Text] [Related]
13. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.
Gervois N; Heuze F; Diez E; Jotereau F
Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
15. T cell receptor gene rearrangements and cytotoxic activities of clones isolated from tumour-infiltrating lymphocytes (TIL) from melanoma patients.
Pandolfi F; Boyle LA; Trentin L; Oliva A; Kurnick JT
Clin Exp Immunol; 1994 Jan; 95(1):141-7. PubMed ID: 8287599
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
17. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
Itoh K; Platsoucas CD; Balch CM
J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
[TBL] [Abstract][Full Text] [Related]
18. Human tumor-infiltrating CD4+ T cells react to B cell lines expressing heat shock protein 70.
Yoshino I; Goedegebuure PS; Peoples GE; Lee KY; Eberlein TJ
J Immunol; 1994 Nov; 153(9):4149-58. PubMed ID: 7930618
[TBL] [Abstract][Full Text] [Related]
19. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.
Pandolfino MC; Viret C; Gervois N; Guilloux Y; Davodeau F; Diez E; Jotereau F
Eur J Immunol; 1992 Jul; 22(7):1795-802. PubMed ID: 1623924
[TBL] [Abstract][Full Text] [Related]
20. Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.
Nielsen M; Presti M; Sztupinszki Z; Jensen AWP; Draghi A; Chamberlain CA; Schina A; Yde CW; Wojcik J; Szallasi Z; Crowther MD; Svane IM; Donia M
Cancer Immunol Res; 2022 Oct; 10(10):1254-1262. PubMed ID: 35969233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
